TITLE

Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine-or Efavirenz-Based Antiretroviral Therapy

AUTHOR(S)
Parienti, Jean-Jacques; Massari, Véronique; Descamps, Diane; Vabret, Astrid; Bouvet, Elisabeth; Larouzé, Bernard; Verdon, Renaud
PUB. DATE
May 2004
SOURCE
Clinical Infectious Diseases;5/1/2004, Vol. 38 Issue 9, p1311
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) increases with the wider use of this class of antiretroviral therapy. The association between adherence and resistance to NNRTI-based regimens is poorly understood. Predictors of virologic failure and resistance according to a baseline evaluation of nonadherence risk factors were determined in a cohort of 71 human immunodeficiency virus (HIV)-infected patients with early virologic response who received an NNRTI-based regimen. During the median follow-up of 29 months, 20 (28%) of 71 patients experienced virologic failure with an NNRTI-based regimen. Virologic failure was associated with repeated drug holidays (≥48 h of unplanned drug cessation), depression, younger age, and low adherence to therapy during baseline evaluation. Moreover, repeated drug holidays was the only risk factor for developing a major mutation conferring cross-resistance to the NNRTI class (hazard ratio, 22.5; 95% confidence interval, 2.8-180.3; P < .0001). Patients' previous adherence to therapy and drugs genetic barriers, not only the number of pills or doses involved, should be taken into consideration in the decision to simplify highly active antiretroviral therapy.
ACCESSION #
13058837

 

Related Articles

  • A Simple, Dynamic Measure of Antiretroviral Therapy Adherence Predicts Failure to Maintain HIV-1 Suppression. Gross, Robert; Yip, Benita; Re III, Vincent Lo; Wood, Evan; Alexander, Christopher S.; Harrigan, P. Richard; Bangsberg, David R.; Montaner, Julio S. G.; Hogg, Robert S. // Journal of Infectious Diseases;10/15/2006, Vol. 194 Issue 8, p1108 

    Background. High levels of antiretroviral therapy adherence are important for human immunodeficiency virus type 1 (HIV-1) suppression, yet the magnitude of adherence required to maintain it is less well characterized. Furthermore, methods to accommodate changes in adherence over time are...

  • Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam. Huong, D. T. M.; Bannister, W.; Phong, P. T.; Kirk, O.; Peters, L. // International Journal of STD & AIDS;Nov2011, Vol. 22 Issue 11, p659 

    The objective of our study was to investigate factors associated with virological failure in 100 consecutive HIV-1 infected Vietnamese adults who initiated antiretroviral therapy (ART) from June 2007 to June 2008. Data were collected from medical records, and a structured questionnaire was used...

  • Delayed diagnosis of HIV-associated thrombocytopenia in a man of 70. Shavit, Linda; Grenader, Tal // Journal of the Royal Society of Medicine;Nov2005, Vol. 98 Issue 11, p515 

    The article discusses a medical case involving a man who was diagnostically delayed of HIV-associated thrombocytopenia. Failure to consider HIV among individuals who are 50 or older may have damaging consequences. A man was brought to the emergency room after weeks of being ill. He then...

  • Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. Squires, Kathleen E.; Johnson, Margaret; Rong Yang; Uy, Jonathan; Sheppard, Louise; Absalon, Judith; McGrath, Donnie // Journal of Antimicrobial Chemotherapy (JAC);Feb2011, Vol. 66 Issue 2, p363 

    Objectives To examine whether the overall results of the CASTLE study pertain to both genders, we analysed the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir in 277 female and 606 male patients in the open-label, multinational trial over 96 weeks. The trial is registered...

  • Should Patients with Drug-Resistant HIV-1 Continue to Receive Antiretroviral Therapy? Frenkel, Lisa M.; Mullins, James I. // New England Journal of Medicine;02/15/2001, Vol. 344 Issue 7, p520 

    Editorial. Discusses a study published in the February 15, 2001 issue of the 'New England Journal of Medicine' which demonstrates that among HIV-1 patients with incomplete suppression of viral replication, HIV-1 plasma levels may be significantly lower with antiretroviral than if it were...

  • Viral and Latent Reservoir Persistence in HIV-1--Infected Patients on Therapy. Hwijin Kim; Perelson, Alan S. // PLoS Computational Biology;Oct2006, Vol. 2 Issue 10, p1232 

    Despite many years of potent antiretroviral therapy, latently infected cells and low levels of plasma virus have been found to persist in HIV-infected patients. The factors influencing this persistence and their relative contributions have not been fully elucidated and remain controversial....

  • AIDS-defining illness diagnosed within 90 days after starting highly active antiretroviral therapy among patients from the TREAT Asia HIV Observational Database. Zhou, J.; Paton, N. I.; Ditangco, R. // International Journal of STD & AIDS;Jul2007, Vol. 18 Issue 7, p446 

    Using data from TREAT Asia HIV Observational Database (TAHOD), this paper aims to assess the rate of, and factors associated with the diagnosis of new AIDS-defining illness (ADI) within 90 days after antiretroviral treatment. Patients starting three or more antiretroviral combinations and having...

  • New therapeutic strategies for raltegravir. Garrido, Carolina; Soriano, Vincent; de Mendoza, Carmen // Journal of Antimicrobial Chemotherapy (JAC);Feb2010, Vol. 65 Issue 2, p218 

    Raltegravir (Isentress®) is the first approved HIV integrase inhibitor. Agents in this class target a different viral enzyme compared with agents inhibiting reverse transcriptase and protease. A wide number of patients are currently susceptible to integrase inhibitors, including heavily...

  • Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Fellay, Jacques; Marzolini, Catia; Decosterd, Laurent; Golay, Kerry; Baumann, Pierre; Buclin, Thierry; Telenti, Amalio; Eap, Chin // European Journal of Clinical Pharmacology;Feb2005, Vol. 60 Issue 12, p865 

    Objective: To measure the in vivo variations of CYP3A activity induced by anti-HIV drugs in human immunodeficiency virus (HIV)1-positive patients. Methods: A low oral dose of midazolam (MID) (0.075 mg) was given to the patients and the 30-mm total 1-OH midazolam (1-OHMID)/MID ratio was deter-...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics